News | Prostate Cancer | November 19, 2018

Validation study from NRG-RTOG 0521 also suggests no association between elevated C-reactive protein and disease-free survival

Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer

November 19, 2018 — Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment interleukin 10 (IL-10) were linked to lower rates of disease-free survival (DFS). The data suggests there is no association between an elevated level of C-reactive protein (CRP) and DFS. Results were presented at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Oct. 21-24 in San Antonio, Texas.

The initial study, NRG-RTOG 0521, indicated that elevated CRP levels, a marker of inflammation, were directly associated with shorter biochemical failure-free survival after radiotherapy for patients with high-risk prostate cancer. During this study, serum samples were collected from 202 participants and banked for future biomarker validation. Researchers measured multiple serum immuno-inflammatory cytokines in addition to CRP levels. The primary objective for the validation study was to determine the association between CRP levels and DFS from time of patient randomization, and additional objectives included the correlation of cytokine levels with DFS and toxicity events due to radiotherapy.

“Although CRP levels did not correlate with DFS, the association of higher baseline levels of IL-10 with poorer outcome supports the claim that there may be an interaction between host pretreatment immune inflammatory state and the outcomes for the patient following radiotherapy treatment. I believe that future investigation into anti-inflammatory medical intervention for patients with prostate cancer in association to radiotherapy would be worthwhile,” stated William A. Hall, M.D., an assistant professor of radiation oncology at the Medical College of Wisconsin and lead author of this abstract.

Serum immune-inflammatory cytokines that were studied included:

  • Monocyte chemotactic protein-1 (MCP-1);
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF);
  • Interferon gamma (IFN-γ);
  • IL-1b;
  • IL-2;
  • IL-4;
  • IL5;
  • IL-6;
  • IL-8;
  • IL-10;
  • IL-12;
  • IL-13;
  • IL-17A;
  • IL-23; and
  • Tumor necrosis factor (TNFα).

In addition to the association between IL-10 and DFS, IL-12 and IL-13 were also associated with grade 2 or higher cystitis, or inflammation of the bladder.

For more information: www.astro.org


Related Content

News | Radiation Oncology

September 26, 2022 — Cleveland Clinic received a $7.9 million five-year grant from the National Cancer Institute at the ...

Time September 26, 2022
arrow
News | Women's Health

September 20, 2022 — Scientists from The Tisch Cancer Institute have uncovered a mechanism by which certain breast ...

Time September 20, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

September 15, 2022 — University of Minnesota Twin Cities scientists and engineers have found a way to improve the ...

Time September 15, 2022
arrow
News | Radiation Therapy

September 15, 2022 — The intestine is very susceptible and is affected by the harsh conditions caused by DNA-altering ...

Time September 15, 2022
arrow
News | Treatment Planning

September 12, 2022 — Sunnybrook Health Sciences Centre, one of Canada’s largest hospitals, offers a highly specialized ...

Time September 12, 2022
arrow
News | Prostate Cancer

September 8, 2022 — In prostate cancer patients experiencing recurrence following a radical prostatectomy, imaging with ...

Time September 08, 2022
arrow
News | Radiology Business

September 8, 2022 — Hoag Memorial Hospital Presbyterian has been named a Radiopharmaceutical Therapy Center of ...

Time September 08, 2022
arrow
News | Radiology Business

September 7, 2022 — Accuray Incorporated announced the company is joining forces with Genolier Innovation Hub, a fully ...

Time September 07, 2022
arrow
News | Radiation Therapy

September 2, 2022 — A key milestone and partnership for the clinical implementation of upright radiotherapy has been ...

Time September 02, 2022
arrow
News | Proton Therapy

September 2, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, today ...

Time September 02, 2022
arrow
Subscribe Now